Today’s the Day: Lilly and Novo Are Set for a White House Deal on Obesity

And Novo’s earnings report sheds light on the Medicare obesity market and the impact of IRA “negotiations”

Nov 6, 2025

Subscribe to Cost Curve Apex to read the rest.

Upgrade to Apex to get access to this post and other subscriber-only content.

No posts found